| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Carlo Calabrese | Q43905288 |
| P2093 | author name string | Massimo Campieri | |
| Claudia Morselli | |||
| Fernando Rizzello | |||
| Paolo Gionchetti | |||
| Rosy Tambasco | |||
| Samuel Davies | |||
| Karen-M Lammers | |||
| Lucia Sollazzi | |||
| P2860 | cites work | Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 |
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial | Q28213579 | ||
| A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result | Q28260707 | ||
| The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat | Q28263005 | ||
| The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats | Q28283634 | ||
| Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease | Q30310154 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Medical therapy for induction and maintenance of remission in pouchitis: a systematic review | Q33535513 | ||
| How to do without steroids in inflammatory bowel disease | Q33853564 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice | Q34006798 | ||
| Double blind, placebo controlled trial of metronidazole in Crohn's disease | Q34394436 | ||
| Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial | Q34410821 | ||
| Diagnosis and treatment of perianal fistulas in Crohn disease | Q34442389 | ||
| Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. | Q34504027 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease | Q34523071 | ||
| Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis | Q34525343 | ||
| Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis | Q34528243 | ||
| Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis | Q34530929 | ||
| A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease | Q34560319 | ||
| Role of microecology in chronic inflammatory bowel diseases | Q35056356 | ||
| T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans | Q35355393 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. | Q35595783 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when | Q36036286 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study | Q40820338 | ||
| Protective effect of metronidazole in experimentalulcerative colitis | Q40866948 | ||
| Metronidazole in Crohn's disease. A double blind cross-over clinical trial | Q40872791 | ||
| Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis | Q41703188 | ||
| Role of intestinal microflora in chronic inflammation and ulceration of the rat colon | Q41810007 | ||
| Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice | Q42128973 | ||
| Preliminary study of ciprofloxacin in active Crohn's disease | Q42169291 | ||
| Metronidazole therapy for perineal Crohn's disease: a follow-up study | Q42263945 | ||
| Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. | Q42674728 | ||
| Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment | Q43005855 | ||
| Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis | Q43328233 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis | Q43719249 | ||
| Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. | Q43746137 | ||
| A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis | Q43807182 | ||
| Variable response to probiotics in two models of experimental colitis in rats. | Q44231461 | ||
| Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis | Q44319566 | ||
| A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. | Q50968026 | ||
| Open label trial of oral clarithromycin in active Crohn's disease. | Q53910434 | ||
| Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. | Q54589903 | ||
| An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. | Q54727809 | ||
| Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. | Q55033133 | ||
| Probiotics | Q57241205 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice | Q59120727 | ||
| Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice | Q59881087 | ||
| The efficacy of tobramycin in the treatment of ulcerative colitis | Q67263770 | ||
| Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum | Q68319017 | ||
| Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) | Q70823350 | ||
| Healing of perineal Crohn's disease with metronidazole | Q71266824 | ||
| Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection | Q72281835 | ||
| Mechanisms of acute and chronic intestinal inflammation induced by indomethacin | Q72669268 | ||
| Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis | Q72688420 | ||
| Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora | Q73092300 | ||
| A meta-analysis of antimycobacterial therapy for Crohn's disease | Q73531563 | ||
| Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Q73837821 | ||
| Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice | Q73838431 | ||
| Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? | Q74126152 | ||
| Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum | Q74133428 | ||
| A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) | Q74623807 | ||
| Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study | Q77494204 | ||
| Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice | Q77659986 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| probiotics | Q1816730 | ||
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 3306-3313 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Antibiotics and probiotics in treatment of inflammatory bowel disease | |
| P478 | volume | 12 |
| Q60177300 | A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis |
| Q37260395 | A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis |
| Q43181113 | Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity |
| Q37097054 | Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. |
| Q34740052 | Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. |
| Q92309963 | Antibiotics and probiotics in inflammatory bowel disease: when to use them? |
| Q24240436 | Antibiotics for induction of remission in ulcerative colitis |
| Q55081727 | Comparison of maintenance effect of probiotics and aminosalicylates on ulcerative colitis: A meta-analysis of randomized controlled trials. |
| Q87279723 | Cooked navy and black bean diets improve biomarkers of colon health and reduce inflammation during colitis |
| Q33386647 | Differential effects of Bifidobacterium pseudolongum strain Patronus and metronidazole in the rat gut |
| Q54332880 | Differential stimulation of peripheral blood mononuclear cells in Crohn's disease by fungal glycans. |
| Q41875201 | Diverticular disease: A therapeutic overview |
| Q43460878 | Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials |
| Q54492437 | Enteroantigen (eAg)-binding B lymphocytes in the mouse - phenotype, distribution, function and eAg-specific antibody secretion. |
| Q37073806 | Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease |
| Q41901947 | Heat-killed VSL#3 ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in rats |
| Q43441764 | Impaired inactivation of digestive proteases: a factor that may have confounded the efficacy of antibiotics aimed at reducing the exposure to luminal bacteria and their components |
| Q37071664 | Infections and autoimmunity: a panorama |
| Q34168490 | Infectious etiopathogenesis of Crohn's disease |
| Q33437877 | Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation |
| Q37111200 | Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk |
| Q35435106 | Lactobacillus plantarum CECT 7315/7316 intake modulates the acute and chronic innate inflammatory response |
| Q34604605 | Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. |
| Q37123770 | Microbial host interactions in IBD: implications for pathogenesis and therapy |
| Q45406923 | Oral nanotherapeutics: effect of redox nanoparticle on microflora in mice with dextran sodium sulfate-induced colitis |
| Q39436977 | Probiotics Lactobacillus plantarum and bifidobacterium B94: cognitive function in demyelinated model |
| Q34588415 | Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. |
| Q36615982 | Probiotics increase T regulatory cells and reduce severity of experimental colitis in mice |
| Q37528655 | Review article: the current and evolving treatment of colonic diverticular disease |
| Q34831072 | Role of conventional therapies in the era of biological treatment in Crohn's disease |
| Q33975300 | Stem cells as potential therapeutic targets for inflammatory bowel disease |
| Q36365170 | Tanshinone IIA ameliorates dextran sulfate sodium-induced inflammatory bowel disease via the pregnane X receptor |
| Q33919752 | The intestinal microbiota plays a role in Salmonella-induced colitis independent of pathogen colonization |
| Q26860722 | The role of gut microbiota in immune homeostasis and autoimmunity |
| Q36077378 | Transplantation of a bacterial consortium ameliorates trinitrobenzenesulfonic acid-induced colitis and intestinal dysbiosis in rats. |
Search more.